FAKTOR-OPTIONSSCHEIN - VALNEVA SE Share Price

Certificat

DE000MA8QPU8

Delayed Börse Stuttgart 02:38:20 07/06/2024 pm IST
0.032 EUR 0.00% Intraday chart for FAKTOR-OPTIONSSCHEIN - VALNEVA SE
Current month-8.57%
1 month+23.08%
Date Price Change
07/24/07 0.032 0.00%
06/24/06 0.032 -3.03%
05/24/05 0.033 -5.71%
04/24/04 0.035 -5.41%
03/24/03 0.037 +5.71%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 02:38 pm IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying VALNEVA
Issuer Morgan Stanley
WKN MA8QPU
ISINDE000MA8QPU8
Date issued 02/09/2021
Strike 1.936
Maturity Unlimited
Parity 59.62 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 13.18
Lowest since issue 0.021

Company Profile

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Sector
-
More about the company

Ratings for Valneva

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Valneva

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.872 EUR
Average target price
8.967 EUR
Spread / Average Target
+131.58%
Consensus